Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging

References

• Brand JM, Meller B, Von Hof K, Luhm J, Bähre M, Kirchner H, Frohn C. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev. 2004;13:307–14.
   PubMedGoogle Scholar
• Koehl U, Sörensen J, Esser R, Zimmermann S, Grüttner HP, Tonn T, . IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33:261–6.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–7.
   PubMed Web of Science ®Google Scholar
• Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625–32.
   PubMed Web of Science ®Google Scholar
• Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, . A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1781–9.
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, . A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98–107.
   PubMed Web of Science ®Google Scholar
• Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20:123–37.
   PubMed Web of Science ®Google Scholar
• Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJK. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 2003; 24:603–9.
   PubMed Web of Science ®Google Scholar
• Canadian Cancer Society Steering Committee. Canadian Cancer Statistics 2010: Canadian Cancer Society; Toronto, 2010
   Google Scholar
• Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, . Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010;59:1739–44.
   PubMed Web of Science ®Google Scholar
• Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, . TCGF (IL 2)-receptor inducing factor (s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol. 1985;134:1623–30.
   PubMed Web of Science ®Google Scholar
• Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652–8.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996;24:406–15.
   PubMed Web of Science ®Google Scholar
• Yagita M, Huang C, Umehara H, Matsuo Y, Tabata R, Miyake M, . A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14:922–30.
   PubMed Web of Science ®Google Scholar
• Cheng M, Ma J, Chen Y, Zhang J, Zhao W, Wei H, . Establishment, characterization and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line. Cell Transplant. 2011;20:1731–46.
   Google Scholar
• Tam YK, Martinson JA, Doligosa K, Klingemann HG. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy. 2003;5:259–72.
   PubMed Web of Science ®Google Scholar
• Jha P, Golovko D, Bains S, Hostetter D, Meier R, Wendland MF, Daldrup-Link HE. Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities. Cancer Res. 2010;70:6109–13.
   PubMed Web of Science ®Google Scholar
• Matera L, Galetto A, Bello M, Baiocco C, Chiappino I, Castellano G, . In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma. J Transl Med. 2006;4:49.
   PubMed Web of Science ®Google Scholar
• Melder RJ, Brownell AL, Shoup TM, Brownell GL, Jain RK. Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors. Cancer Res. 1993;53:5867–71.
   Google Scholar
• Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-J Hematother Stem Cell Res. 2001;10:535–44.
   Google Scholar
• Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, . In vivo tracking of genetically engineered, anti-her2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol. 2005;15:4–13.
   PubMed Web of Science ®Google Scholar
• Meier R, Piert M, Piontek G, Rudelius M, Oostendorp RA, Senekowitsch-Schmidtke R, . Tracking of [18F]fdg- labeled natural killer cells to HER2/neu-positive tumors. Nucl Med Biol. 2008;35:579–88.
   PubMed Web of Science ®Google Scholar
• Tavri S, Jha P, Meier R, Henning TD, Müller T, Hostetter D, . Optical imaging of cellular immunotherapy against prostate cancer. Mol Imaging. 2009;8:15–26.
   Google Scholar
• Lim YT, Cho MY, Noh YW, Chung JW, Chung BH. Near-infrared emitting fluorescent nanocrystals-labeled natural killer cells as a platform technology for the optical imaging of immunotherapeutic cells-based cancer therapy. Nanotechnology. 2009;20:475102.
   PubMed Web of Science ®Google Scholar
• Meier R, Golovko D, Tavri S, Henning TD, Knopp C, Piontek G, . Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging. Magn Reson Med. 2011;65:756–63.
   PubMed Web of Science ®Google Scholar
• Foster-Gareau P, Heyn C, Alejski A, Rutt BK. Imaging single mammalian cells with a 1.5 T clinical MRI scanner. Mag Reson Med. 2003;49:968–71.
   PubMed Web of Science ®Google Scholar
• Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, Foster PJ. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Mag Reson Med. 2006;55:23–9.
   PubMed Web of Science ®Google Scholar
• Shapiro EM, Sharer K, Skrtic S, Koretsky AP. In vivo detection of single cells by MRI. Magn Reson Med. 2006;55:242–9.
   PubMed Web of Science ®Google Scholar
• Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, . Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology. 2003;228:480–7.
   PubMed Web of Science ®Google Scholar
• Bernas LM, Foster PJ, Rutt BK. Imaging iron-loaded mouse glioma tumors with bssfp at 3 T. Mag Reson Med. 2010;64: 23–31.
   Google Scholar
• Ramadan SS, Heyn C, MacKenzie LT, Chambers AF, Rutt BK, Foster PJ. Ex-vivo cellular MRI with b-ssfp: quantitative benefits of 3 T over 1.5 T. Mag Reson Mat Phys Biol Med. 2008;21:251–9.
   Google Scholar
• Gonzalez-Lara LE, Xu X, Hofstetrova K, Pniak A, Brown A, Foster PJ. In vivo magnetic resonance imaging of spinal cord injury in the mouse. J Neurotra. 2009;26:753–62.
   PubMedGoogle Scholar
• Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S, Keating A. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol. 2005;33:1160–71.
   PubMed Web of Science ®Google Scholar
• Kozlowski JM, Fidler IJ, Campbell D, Xu Z, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 1984;44:3522–9.
   PubMedGoogle Scholar
• Rosset A, Spadola L, Ratib O. Osirix: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging. 2004;17:205–16.
   PubMed Web of Science ®Google Scholar
• McFadden C, Mallett CL, Foster PJ. Labeling of multiple cell lines using a new iron oxide agent for cell tracking by MRI. Cont Media Mol Imag. 2011;6:514–22.
   Google Scholar
• Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, . Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2008;57:411–23.
   PubMed Web of Science ®Google Scholar
• Suck G, Branch DR, Keating A. Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol. 2006;82:355–61.
   PubMed Web of Science ®Google Scholar
• Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 2004;114:560–568.
   PubMedGoogle Scholar
• Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med. 1991;174:479–88.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, . Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.
   PubMed Web of Science ®Google Scholar
• Petersen CC, Petersen MS, Agger R, Hokland ME. Accumulation in tumor tissue of adoptively transferred T cells: a comparison between intravenous and intraperitoneal injection. J Immunother. 2006;29:241–9.
   PubMed Web of Science ®Google Scholar
• Heyn C, Bowen CV, Rutt BK, Foster PJ. Detection threshold of single spio-labeled cells with FIESTA. Mag Reson Med. 2005;53:312–20.
   PubMed Web of Science ®Google Scholar
• Addicott B, Willman M, Rodriguez J, Padgett K, Han D, Berman D, . Mesenchymal stem cell labeling and in vitro MR characterization at 1.5 T of new SPIO contrast agent: Molday ION rhodamine-b™. Cont Media Mol Imag. 2011;6:7–18.
   Google Scholar
• Rohani R, de Chickera SN, Willert C, Chen Y, Dekaban GA, Foster PJ. In vivo cellular MRI of dendritic cell migration using micrometer-sized iron oxide (MPIO) particles. Mol Imaging Biol. 2011;13:679–94.
   Google Scholar